Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Kowolenko Michael
   2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [BIIB] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Pharm Ops & Technology
(Last)
(First)
(Middle)
14 CAMBRIDGE CENTER		 3. Date of Earliest Transaction (Month/Day/Year)
07/25/2007
(Street)

CAMBRIDGE, MA 02142		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/25/2007   M(1)   3,450 A $ 42.12 21,573.856 (2) D  
Common Stock 07/25/2007   M(1)   4,356 A $ 37.45 25,929.856 D  
Common Stock 07/25/2007   M(1)   8,438 A $ 43.5 34,367.856 D  
Common Stock 07/25/2007   M(1)   4,263 A $ 44.24 38,630.856 D  
Common Stock 07/25/2007   S(1)   20,507 D $ 58 18,123.856 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to buy) $ 42.12 07/25/2007   M(1)     3,450   (3) 04/01/2012 Common Stock 3,450 (4) 3,450 D  
Stock Option (Right to buy) $ 37.45 07/25/2007   M(1)     4,356   (5) 12/06/2012 Common Stock 4,356 (4) 4,355 D  
Stock Option (Right to buy) $ 43.5 07/25/2007   M(1)     8,438   (6) 02/06/2014 Common Stock 8,438 (4) 14,062 D  
Stock Option (Right to buy) $ 44.24 07/25/2007   M(1)     4,263   (7) 02/06/2016 Common Stock 4,263 (4) 29,837 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Kowolenko Michael
14 CAMBRIDGE CENTER
CAMBRIDGE, MA 02142		       SVP, Pharm Ops & Technology  

Signatures

 Robert A. Licht, Attorney in Fact for Michael Kowolenko   07/27/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
(2) Includes 117.9266 shares acquired on March 30, 2007 and 39.4994 shares acquired on June 29, 2007 under the Biogen Idec Inc. Employee Stock Purchase Plan.
(3) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 04/01/02.
(4) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
(5) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
(6) The stock options become exercisable in four (4) equal annual installments on 12/31/04, 12/31/05, 12/31/06 and 12/31/07.
(7) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/06/06.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.